Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Gilead Sciences

Given inelastic demand, rapid breakthroughs, and government initiatives, the biotech industry looks well-positioned to thrive. So, quality biotech stocks Gilead Sciences (GILD), Biogen (BIIB), and Alkermes (ALKS) could be worth owning. Read on.

StockNews.com

Gilead Sciences Stock Reaches 80-Plus Relative Strength Rating Benchmark

Gilead Sciences shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.

Investors Business Daily

Markets Today: Stocks Slip Ahead of U.S. Debt Ceiling Talks

Morning Markets June E-Mini S&P 500 futures (ESM2 3) this morning are down -0.26%, and June Nasdaq 100 E-Mini futures (NQM2 3) are down -0.21%. U.S. stock index futures this morning are moderately lower as the markets await any new developments on the debt ceiling stalemate. President Biden will meet...

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Pharmaceutical executives challenge Texas court’s abortion pill ruling

Gilead Sciences and Pfizer join amicus brief

The Independent UK

2 Biotech Stocks to Buy Hand Over Fist in March

The biotech industry is expected to expand rapidly, driven by significant advancements and government initiatives. Furthermore, this sector tends to be relatively defensive and holds up relatively well during downturns. So, fundamentally sound biotech stocks Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX) might be ideal buys now. Keep reading.

StockNews.com

3 Dividend Paying Stocks to Buy in March

With the stock market anticipated to stay volatile due to persistent concerns about high inflation, interest rate hikes, and a recession, fundamentally solid dividend stocks Gilead Sciences (GILD), CVS Health (CVS), and Altria (MO) might be great buys for a steady income stream. Keep reading.

StockNews.com

It’s Time to Buy Up These 3 Growth Stocks In 2023

While higher rates have hurt growth stocks last year, 2023 could be the year of growth stocks gaining momentum. Amid rising optimism, investors could consider buying fundamentally strong growth stocks Gilead Sciences (GILD), Jazz (JAZZ), and Masonite International (DOOR) this year. Keep reading.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Gilead Snags Another Cancer Win On The Heels Of Its Best Growth In 7 Years

Gilead Sciences followed up a strong quarterly report with a third FDA approval for cancer drug Trodelvy, and GILD stock popped.

Investors Business Daily

2 Biotech Stocks to Buy and 1 to Avoid Like the Plague

The biotech industry is expected to witness solid growth driven by growing government initiatives and increasing demand across several sectors. While we think fundamentally sound biotech stocks Gilead Sciences (GILD) and United Therapeutics (UTHR) could be solid buys this year, Bionano Genomics (BNGO) could be best avoided considering its fundamental…

StockNews.com

3 Safe High-Dividend Stocks to Buy Right Now

While inflation pressures seem to be cooling, the Fed is expected to continue with its rate hikes, raising the chances of a recession this year. Hence, high-dividend stocks AbbVie (ABBV), Gilead Sciences (GILD), and Marine Products (MPX) might be solid buys for steady income amid current uncertainties. Keep reading.

StockNews.com

Gilead Sciences Snags FDA Approval For Twice-Yearly HIV Shot

Gilead won Food and Drug Administration approval for a twice-a-year HIV treatment called Sunlenca on Thursday.

Investors Business Daily

Up More than 19% In 2022, Is Gilead Sciences Still a Buy?

Gilead Sciences (GILD) beat revenue and earnings estimates in the previous quarter and upgraded its guidance for fiscal 2022. Having risen more than 19% year-to-date, is GILD still a buy? Read on to learn our view.

StockNews.com

Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences

Recent initial public offering Arcellx forged a $325 million cancer deal with Gilead Sciences on Friday, and the IPO stock broke out.

Investors Business Daily

See Why Gilead's Cancer Business Is Driving The Stock To A Fever Pitch

Gilead Sciences' first-in-class cancer drug and GILD stock are finally hitting their stride. The oncology business is growing bullishly.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

The Conversation

Monkeypox: latest data reveals how the virus has affected women and non-binary people

Since May 2022, a global outbreak of human monkeypox infections has been reported in over 78,000 people. So far, infections have overwhelmingly occurred in sexually active men who have sex with men.

StockNews.com

Is Gilead Sciences Still a Buy Post COVID-19?

Gilead Sciences’ (GILD) popular covid product Veklury (Remdisivir) witnessed declining sales in the post-pandemic era. However, the company’s top line, excluding Veklury, has seen steady growth. Moreover, despite ongoing market volatility, the stock has registered stable gains. So, let’s find out if GILD is still a buy in the post-covid…

Benzinga

Gilead Sciences Unusual Options Activity

Someone with a lot of money to spend has taken a bullish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022

Upgrades

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Check Out What Whales Are Doing With GILD

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2022

Upgrades

Investors Business Daily

Gilead Breaks Out In Bullish Volume As Its Cancer Drug Sales Nearly Double

Gilead Sciences reported 79% growth for its cancer drugs, helping beat expectations. On Friday, GILD stock broke out.

Reuters

U.S. sends experimental antibody, antiviral drug to Uganda for Ebola outbreak

The United States sent Gilead Sciences' remdesivir and Mapp Biopharmaceutical Inc's experimental Ebola antibody drug MBP134 to Uganda last week to help safeguard healthcare workers responding to an outbreak that has infected 60 people and killed 44, U.S. government sources told Reuters.

Benzinga

Gilead Sciences Whale Trades Spotted

Someone with a lot of money to spend has taken a bearish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

StockNews.com

3 Biotech Stocks to Buy for Q4 and 1 to Avoid

Favorable federal investments are anticipated to fuel further expansion in the biotech industry. Given the sector’s good prospects, quality biotech stocks Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) could be ideal buys. However, fundamentally weak stock Intra-Cellular Therapies (ITCI) might be best avoided. Read on….

Benzinga

What Are Whales Doing With Gilead Sciences

A whale with a lot of money to spend has taken a noticeably bullish stance on Gilead Sciences. Looking at options history for Gilead Sciences (NASDAQ:GILD) we detected 17 strange trades.

1 2 3 4

People

Joe Biden

63,441 stories

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Advanced Micro Devices

331 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.